Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Overall survival in patients with acute lymphoblastic leukemia in the aya population, treated with modified pediatric chemotherapeutic schemes, a real-life study

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSilvia-María Sandoval-CamposLALuara-Luz Arana-lunaJAJose Alvarez

Discussion

Loading...

Member takes

Overview

Historical cohort study demonstrates improved overall survival in adolescents and young adults with acute lymphoblastic leukemia through modified chemotherapy regimens, highlighting the importance of

Key Points

  • To evaluate the overall survival rate in adolescents and young adults (AYA) with acute lymphoblastic leukemia treated with modified pediatric chemotherapy regimens.
  • Historical cohort study conducted from patient registry of a referral hospital.
  • Analysis of 98 patients aged 15-45 with phenotype B who received first-line treatment using modified pediatric chemotherapy regimens.
  • Treatment protocol involved LALÍN regimen, dasatinib for Philadelphia-positive patients, and L-asparaginase for negative patients.
  • 93.8% of patients achieved complete response after induction treatment.
  • 3-year overall survival rate was 32.5%, with a median survival rate of 44 months.
  • Negative MRD after induction was the only significant predictor of overall survival.

Cite This Study

Sandoval-Campos et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236decbhttps://doi.org/10.1182/blood-2025-6844
View Full Paper
Ask AI
Bookmark
Share